Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Derivation and Validation of Novel Phenotypes of Multiple Organ Dysfunction Syndrome in Critically Ill Children.

Tytuł:
Derivation and Validation of Novel Phenotypes of Multiple Organ Dysfunction Syndrome in Critically Ill Children.
Autorzy:
Sanchez-Pinto LN; Critical Care, Department of Pediatrics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.; Health and Biomedical Informatics, Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.; Division of Critical Care Medicine, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois.
Stroup EK; Driskill Graduate Program, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
Pendergrast T; Division of Critical Care Medicine, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois.
Pinto N; Section of Critical Care, Department of Pediatrics, The University of Chicago, Chicago, Illinois.
Luo Y; Health and Biomedical Informatics, Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
Źródło:
JAMA network open [JAMA Netw Open] 2020 Aug 03; Vol. 3 (8), pp. e209271. Date of Electronic Publication: 2020 Aug 03.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural
Język:
English
Imprint Name(s):
Original Publication: Chicago, IL : American Medical Association, [2018]-
MeSH Terms:
Critical Illness*/epidemiology
Critical Illness*/mortality
Multiple Organ Failure*/classification
Multiple Organ Failure*/diagnosis
Multiple Organ Failure*/epidemiology
Multiple Organ Failure*/mortality
Organ Dysfunction Scores*
Child ; Child, Preschool ; Female ; Humans ; Infant ; Intensive Care Units, Pediatric ; Male ; Phenotype ; Prognosis ; Retrospective Studies
References:
Pediatr Crit Care Med. 2019 Dec;20(12):1137-1146. (PMID: 31568246)
Pediatr Crit Care Med. 2017 Mar;18(3_suppl Suppl 1):S50-S57. (PMID: 28248834)
Pediatr Crit Care Med. 2017 Mar;18(3_suppl Suppl 1):S1-S3. (PMID: 28248828)
BMC Bioinformatics. 2010 Jul 02;11:367. (PMID: 20598126)
Ann Intern Med. 2007 Oct 16;147(8):573-7. (PMID: 17938396)
Lancet Respir Med. 2014 Aug;2(8):611-20. (PMID: 24853585)
Intensive Care Med. 2011 Mar;37(3):525-32. (PMID: 21153402)
Am J Respir Crit Care Med. 2019 Aug 1;200(3):327-335. (PMID: 30789749)
N Engl J Med. 2018 Mar 01;378(9):809-818. (PMID: 29490185)
Crit Care Med. 2006 Jan;34(1):22-30. (PMID: 16374152)
Crit Care Med. 2016 Feb;44(2):275-81. (PMID: 26584195)
Pediatr Crit Care Med. 2017 Jan;18(1):8-16. (PMID: 28060151)
BMC Pediatr. 2014 Aug 08;14:199. (PMID: 25102958)
Pediatr Res. 2007 Nov;62(5):597-603. (PMID: 17805202)
Intensive Care Med. 1999 Jul;25(7):686-96. (PMID: 10470572)
Crit Care Med. 2018 Mar;46(3):e242-e249. (PMID: 29252929)
Crit Care Med. 2017 Feb;45(2):e124-e131. (PMID: 27632680)
JAMA Pediatr. 2017 Oct 2;171(10):e172352. (PMID: 28783810)
N Engl J Med. 2008 Jan 10;358(2):111-24. (PMID: 18184957)
Science. 2015 Mar 13;347(6227):1201-2. (PMID: 25766219)
Crit Care Med. 2000 Jul;28(7):2193-200. (PMID: 10921540)
Pediatr Crit Care Med. 2019 Mar;20(3S Suppl 1):S1-S82. (PMID: 30829890)
Crit Care Med. 2013 Jul;41(7):1761-73. (PMID: 23685639)
Intensive Care Med. 2015 May;41(5):814-22. (PMID: 25851384)
N Engl J Med. 2018 Mar 01;378(9):797-808. (PMID: 29347874)
Crit Care Med. 1996 May;24(5):743-52. (PMID: 8706448)
Pediatr Crit Care Med. 2019 Aug;20(8):722-727. (PMID: 31398181)
Int J Burns Trauma. 2012;2(1):1-10. (PMID: 22928162)
Pediatr Crit Care Med. 2013 Jun;14(5):462-6. (PMID: 23628832)
Crit Care. 2015 Sep 15;19:324. (PMID: 26369662)
Crit Care Med. 2018 Apr;46(4):635-636. (PMID: 29360665)
Crit Care. 2016 Oct 15;20(1):329. (PMID: 27741949)
Crit Care Med. 2005 Jul;33(7):1484-91. (PMID: 16003052)
Crit Care. 2017 Oct 18;21(1):257. (PMID: 29047353)
JAMA. 2019 May 28;321(20):2003-2017. (PMID: 31104070)
Crit Care Med. 2018 Jun;46(6):915-925. (PMID: 29537985)
Med Decis Making. 1999 Oct-Dec;19(4):399-410. (PMID: 10520678)
Pediatr Crit Care Med. 2017 Mar;18(3_suppl Suppl 1):S32-S45. (PMID: 28248832)
Am J Respir Crit Care Med. 2015 Feb 1;191(3):309-15. (PMID: 25489881)
Grant Information:
T32 LM012203 United States LM NLM NIH HHS; R21 LM012618 United States LM NLM NIH HHS; R21 HD096402 United States HD NICHD NIH HHS
Entry Date(s):
Date Created: 20200812 Date Completed: 20201230 Latest Revision: 20220716
Update Code:
20240105
PubMed Central ID:
PMC7420303
DOI:
10.1001/jamanetworkopen.2020.9271
PMID:
32780121
Czasopismo naukowe
Importance: Multiple organ dysfunction syndrome (MODS) is a dynamic and heterogeneous process associated with high morbidity and mortality in critically ill children.
Objective: To determine whether data-driven phenotypes of MODS based on the trajectories of 6 organ dysfunctions have prognostic and therapeutic relevance in critically ill children.
Design, Setting, and Participants: This cohort study included 20 827 pediatric intensive care encounters among 14 285 children admitted to 2 large academic pediatric intensive care units (PICUs) between January 2010 and August 2016. Patients were excluded if they were older than 21 years or had undergone cardiac surgery. The 6 subscores of the pediatric Sequential Organ Failure Assessment (pSOFA) score were calculated for the first 3 days, including the subscores for respiratory, cardiovascular, coagulation, hepatic, neurologic, and renal dysfunctions. MODS was defined as a pSOFA subscore of at least 2 in at least 2 organs. Encounters were split in a 80:20 ratio for derivation and validation, respectively. The trajectories of the 6 subscores were used to derive a set of data-driven phenotypes of MODS using subgraph-augmented nonnegative matrix factorization in the derivation set. Data analysis was conducted from March to October 2019.
Exposures: The primary exposure was phenotype membership. In the subset of patients with vasoactive-dependent shock, the interaction between hydrocortisone and phenotype membership and its association with outcomes were examined in a matched cohort.
Main Outcomes and Measures: The primary outcome was in-hospital mortality. Secondary outcomes included persistent MODS on day 7, and vasoactive-free, ventilator-free, and hospital-free days. Regression analysis was used to adjust for age, severity of illness, immunocompromised status, and study site.
Results: There were 14 285 patients with 20 827 encounters (median [interquartile range] age 5.2 years [1.5-12.7] years; 11 409 [54.8%; 95% CI, 54.1%-55.5%] male patients). Of these, 5297 encounters (25.4%; 95% CI, 24.8%-26.0%) were with patients who had MODS, of which 5054 (95.4%) met the subgraph count threshold and were included in the analysis. Subgraph augmented nonnegative matrix factorization uncovered 4 data-driven phenotypes of MODS, characterized by a combination of neurologic, respiratory, coagulation, and cardiovascular dysfunction, as follows: phenotype 1, severe, persistent encephalopathy (1019 patients [19.2%]); phenotype 2, moderate, resolving hypoxemia (1828 patients [34.5%]); phenotype 3, severe, persistent hypoxemia and shock (1012 patients [19.1%]); and phenotype 4, moderate, persistent thrombocytopenia and shock (1195 patients [22.6%]). These phenotypes were reproducible in a validation set of encounters, had distinct clinical characteristics, and were independently associated with outcomes. For example, using phenotype 2 as reference, the adjusted hazard ratios (aHRs) for death by 28 days were as follows: phenotype 1, aHR of 3.0 (IQR, 2.1-4.3); phenotype 3, aHR of 2.8 (IQR, 2.0-4.1); and phenotype 4, aHR of 1.8 (IQR, 1.2-2.6). Interaction analysis in a matched cohort of patients with vasoactive-dependent shock revealed that hydrocortisone had differential treatment association with vasoactive-free days across phenotypes. For example, patients in phenotype 3 who received hydrocortisone had more vasoactive-free days than those who did not (23 days vs 18 days; P for interaction < .001), whereas patients in other phenotypes who received hydrocortisone either had no difference or had less vasoactive-free days.
Conclusions and Relevance: In this study, data-driven phenotyping in critically ill children with MODS uncovered 4 distinct and reproducible phenotypes with prognostic relevance and possible therapeutic relevance. Further validation and characterization of these phenotypes is warranted.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies